BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Analysts at Leerink Swann boosted their FY2018 earnings per share estimates for shares of BioMarin Pharmaceutical in a research report issued to clients and investors on Tuesday. Leerink Swann analyst J. Schwartz now forecasts that the firm will post earnings per share of $0.96 for the year, up from their previous estimate of $0.85. Leerink Swann has a “Outperform” rating and a $127.00 price target on the stock.

A number of other research firms have also weighed in on BMRN. Vetr lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $103.86 price target for the company. in a research report on Monday, August 1st. Barclays PLC upped their price target on shares of BioMarin Pharmaceutical from $105.00 to $125.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Stifel Nicolaus upped their price target on shares of BioMarin Pharmaceutical from $107.00 to $113.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Piper Jaffray Cos. upped their price target on shares of BioMarin Pharmaceutical from $107.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, August 5th. Finally, Jefferies Group upped their price target on shares of BioMarin Pharmaceutical from $116.00 to $120.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $118.31.

Earnings History and Estimates for BioMarin Pharmaceutical (NASDAQ:BMRN)

BioMarin Pharmaceutical (NASDAQ:BMRN) traded down 2.11% during mid-day trading on Thursday, hitting $85.04. 1,238,039 shares of the stock traded hands. BioMarin Pharmaceutical has a 12 month low of $62.12 and a 12 month high of $118.48. The company’s market cap is $13.90 billion. The company’s 50 day moving average is $94.91 and its 200 day moving average is $89.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($2.61) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $2.09. The company had revenue of $300.10 million for the quarter, compared to analysts’ expectations of $278.75 million. BioMarin Pharmaceutical had a negative net margin of 54.53% and a negative return on equity of 11.99%. The business’s quarterly revenue was up 20.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.51) EPS.

A number of hedge funds and other institutional investors have recently modified their holdings of BMRN. Adage Capital Partners GP L.L.C. boosted its position in shares of BioMarin Pharmaceutical by 316.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,052,900 shares of the company’s stock valued at $86,843,000 after buying an additional 800,000 shares during the last quarter. ING Groep NV acquired a new position in shares of BioMarin Pharmaceutical during the second quarter valued at about $57,357,000. Pictet Asset Management Ltd. boosted its position in shares of BioMarin Pharmaceutical by 265.1% in the second quarter. Pictet Asset Management Ltd. now owns 968,295 shares of the company’s stock valued at $86,808,000 after buying an additional 703,112 shares during the last quarter. Palo Alto Investors LLC boosted its position in shares of BioMarin Pharmaceutical by 29.6% in the second quarter. Palo Alto Investors LLC now owns 1,737,399 shares of the company’s stock valued at $135,170,000 after buying an additional 397,052 shares during the last quarter. Finally, Eaton Vance Management boosted its position in shares of BioMarin Pharmaceutical by 728.2% in the second quarter. Eaton Vance Management now owns 414,874 shares of the company’s stock valued at $32,277,000 after buying an additional 364,780 shares during the last quarter. Institutional investors own 93.02% of the company’s stock.

In other BioMarin Pharmaceutical news, CEO Jean Jacques Bienaime sold 53,125 shares of the stock in a transaction dated Thursday, September 29th. The shares were sold at an average price of $93.65, for a total transaction of $4,975,156.25. Following the transaction, the chief executive officer now directly owns 431,709 shares in the company, valued at approximately $40,429,547.85. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director V Bryan Lawlis sold 6,400 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $95.01, for a total transaction of $608,064.00. Following the transaction, the director now owns 20,260 shares in the company, valued at $1,924,902.60. The disclosure for this sale can be found here. 2.50% of the stock is currently owned by corporate insiders.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

5 Day Chart for NASDAQ:BMRN

Receive News & Stock Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.